Work

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0314-7

Authors: Dustin A. Deming, Ludmila L. Cavalcante, Sam J. Lubner, Daniel L. Mulkerin, Noelle K. LoConte, Jens C. Eickhoff, Jill M. Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin G. Doyle, George Wilding, Austin Duffy, Glenn Liu

Institutions: University of Wisconsin Carbone Cancer Center, National Cancer Institute, National Institutes of Health

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: G1387911743, G42679306, Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis (U01)

OpenAlex ID: W2200675409

FWCI: 1.82

Cites: 17

Cited by: 52

Related to: 10